Tonix Pharmaceuticals posts investor deck spotlighting TONMYA fibromyalgia launch strategy

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

TNXP

0.00
  • Tonix highlighted early commercial traction for TONMYA, launched Nov. 17, 2025, with 1Q’26 net sales of USD 3.7 million.
  • Net sales reached USD 5.1 million from Nov. 17, 2025 to Mar. 31, 2026; more than 2,600 prescribers wrote TONMYA prescriptions.
  • Cash and cash equivalents totaled about USD 185.5 million as of Mar. 31, 2026; no debt; cash runway expected into early Q2’27.
  • Pipeline focus includes TNX-4800 Lyme disease prevention study planned for 1H’27; TNX-1500 Phase 2 planned 2H’26; TNX-2900 Phase 2 planned 1Q’27.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.